

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: November 5, 2004, 13:50:17 ; Search time 74.3927 Seconds
(without alignments)
3081.324 Million cell updates/sec

Title: US-09-937-636-4
Perfect score: 3377

Sequence: 1 MLLPLLSSLGGSQAMDGR.....RBEARMFKGTQADYAEVKFQ 639

Scoring table: BLOSUM62
Gapext 0.5

Searched: 2002273 seqs, 3587299 residues

Total number of hits satisfying chosen parameters: 2002273

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : A_Geneseq_23Sep04:*

1: geneseq_1990s:*

2: geneseq_1990s:*

3: geneseq_2000s:*

4: geneseq_2001s:*

5: geneseq_2002s:*

6: geneseq_2003as:*

7: geneseq_2003bs:*

8: geneseq_2004s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query	Match Length	DB ID	Description
1	3377	100.0	639	AAYB1023	AayB1023 Human sia
2	3377	100.0	63.9	AAY197543	Aay197543 Human Sia
3	3354	99.3	63.9	AAB25580	Aab25580 CD33-like
4	3354	99.3	63.9	ADA27052	Ada27052 Human nov
5	3354	99.3	63.9	ADB86582	Ade86582 Novel hum
6	3338	98.8	69.7	AAB87087	Aau87087 Sialic ac
7	3334	98.7	69.7	ADA27153	Ada27153 Human nov
8	3334	98.7	69.7	ADD26582	Add26582 Sialic-10
9	3334	98.7	69.7	AD137010	Adi37010 Novel hum
10	3334	98.7	69.7	AD18205	Adl18205 Human PRO
11	3299	97.7	62.2	AAYB1075	Aau87075 Sialic ac
12	3174.5	94.0	71.0	ADD19314	Add19314 Human sec
13	2804.5	83.0	54.4	AAUD7074	Aau87074 Sialic ac
14	2790.5	82.6	54.4	AAY1724	Aay41724 Human PRO
15	2790.5	82.6	54.4	AAB44280	Aab44280 Human PRO
16	2790.5	82.6	54.4	AAU19082	Aau19082 Human PRO
17	2790.5	82.6	54.4	ABU8458	Abu8458 Human PRO
18	2790.5	82.6	54.4	ABUB8006	Abu8006 Novel hum
19	2790.5	82.6	54.4	ABUB4321	Abu84321 Human sec
20	2790.5	82.6	54.4	ABRE6195	Abr6195 Human sec
21	2790.5	82.6	54.4	ABR5585	Abr5585 Human sec
22	2790.5	82.6	54.4	ABU99525	Abu99525 Human sec
23	2790.5	82.6	54.4	ABU82764	Abu82764 Human PRO
24	2790.5	82.6	54.4	ABU99885	Abu99885 Novel hum
	32.6			ABR68134	Abu68134 Human sec

ALIGNMENTS

RESULT 1

ID AAW81023 standard; protein; 639 AA.

XX

AC AAW81023;

XX

DT 26-APR-1999 (first entry)

XX

DE Human sialoadhesin family 4 (SAF-1) polypeptide.

XX

SAF-4; sialoadhesin family; human; therapy; diagnosis; cancer; inflammation; autoimmune disease; allergy; asthma; inflammation; cerebellar degeneration; Alzheimer's disease; Parkinson's disease; multiple sclerosis; amyotrophic lateral sclerosis; head injury; septic shock; sepsis; stroke; osteoarthritis; osseointegration; ischaemia; reperfusion injury; cardiovascular disease; kidney disease; liver disease; myocardial infarction; hypertension; aplastic anaemia; myelodysplastic syndrome; baldness; infection.

XX

Homo sapiens.

XX

W09853840-A1.

XX

PD 03-DEC-1998.

XX

PF 27-MAY-1998;

XX

98WO-US010791.

XX

PR 27-MAY-1997;

XX

97US-0047572P.

XX

(SMIK) SMITHKLINE BEECHAM CORP.

XX

PI Kikly KK, Erickson-Miller CL;

XX

DR WPI:1999-080779/07.

XX

N-P5DB; AAV99911.

XX

PT New sialoadhesin family 4 polypeptides and polynucleotides - useful to treat various diseases associated with SAF-4 expression.

XX

PS Claim 1; Page 31; 48pp; English.

XX

CC This is the amino acid sequence of new human sialoadhesin family 4 (SAF-4), as deduced from the nucleotide sequence of an isolated cDNA clone (see AAV9911).

CC producing such polypeptides in transformed host cells using recombinant techniques are disclosed. SAF-4, its agonists and antagonists, and

CC nucleic acid molecules that enhance or inhibit SAF-4 expression, may be

CC used to treat patients in need of enhancement or inhibition of SAF-4

expression or activity. Conditions that may benefit from such treatment include cancer, inflammation, autoimmunity, allergy, asthma, rheumatoid arthritis, CNS inflammation, cerebellar degeneration, Alzheimer's disease, Parkinson's disease, multiple sclerosis, myotrophic lateral sclerosis, head injury, damage and other neurological disorders, septic shock, sepsis, stroke, osteoporosis, osteoarthritis, ischemia, reperfusional injury, cardiovascular disease, liver disease, ischemic injury, myocardial infarction, hypotension, hypertension, AIDS, myelodysplastic syndromes and other haematologic abnormalities, aplastic anaemia, male baldness pattern and bacterial, protozoal, fungal and viral infections related to SAP-4 polypeptide activity. Methods of identifying antagonists/inhibitors are also provided, as well as diagnostic assays for detecting diseases associated with inappropriate SAP-4 activity or levels.

Sequence 63 9 22

Query Match : 100.0% ; Score 3377 ; DB 2 ; Length 639 ;

Best Local Similarity 100.0%; Pred. No. 2.3e-232; Mismatches 0; Indels 0;

1 MLLPYLESSLIGGSOAMDEGRERFWIRVQESVMVPBGLCISVPCPSYPRDWTGS

6.1	FAAVVIEIINGAEEVATNEQNSRLVEMISTRGRQLTGPAAGCNSLVRDAQMDQE
6.1	FKAVTETTKGAPVATNEOSREVEMSTRGRQLTGPAAGCNSLVRDAQMDQE

121 ERGGSYVYNENDGFFPLKVTVLSFTPRPODANTDUTCHYDFSRKGVSAQRTYRIL

121 ERGSYVRYNEMDGGFFLKVTVLSSFTPQDHNTDLITCHVDSRKGVSAQRTRVL

181 RDIVISIRDNNTPALEBPOQOGENPVYLEAKORGQFLRLCAADSOOPATLSTVLO

181 RDLVTSISRNTNTPALEPQPQCNVPYLBAQGQFLRLILCAADSSOPPATLISWTLQN
182

241	<chem>HPWGPRLPLGLEPGVKAQDGSRVTCAENRLGSCORALDLSSVOPBENLRVMVSQNLKAVMS</chem>
242	

3.01 LENLNGNTSLPVLEQOSLCLVCYTHSSPPARLSWTORGQLSPSOPSDPGVLELL

301 LENINGNTSLPVLEGOSLCLVCVTHSSPPARLSWTQRGQVLSPSOPSPGVLELLD
302

361 HEGBFPTCHARHPLGSQHVSLSVHSYSPLLGPSCSWEAEGLHCSSQSAPPS

361 HECEFFTCRHPPLGSQYVLSISVHYSPKLGPSCSWEAELGHCSQSAPAPS
421 GRRTEFGNSSONSPYEMPSACOMANCSTIYCCCTGCCDIPOCMMUTCCG

4.81 DKKGGLISTAFNSNGAPIIGITALFLCLALIMKILPKRTOTETPRFRSHSTY

481 DKKGGLISTAPSNGAFLGIGITALFLCLALIMKILPKRTQTETPRPRFSRHTI

541 NVVPTAGPLAQKRNOQKATPNNSRPTLPPGAPSPESSKRNQQKQYQLPSSPPPKSSTQ

541 NWP#AGL#QKRNQKATPNSPRTPLPPGASSPEKSNOKKQYQLPSSPPPKSSTSQ
560 1 DESEOBELHYATIN#PGVURPRP#ARMPIKGCTOBYARYVKFO 639

601 QESQEELHYATLNPGVVRPPEARMPKGTOQADYAEVKFO 639

ESTATE ?

AAV97543 standard; protein; 639 AA.
D AAV97543

AAY97543 ;

12-FEB-2001 {first entry}

